



12th October, 2017



STOCK INDICES	Closing	1D%	
SENSEX	31833.99	-0.28%	
NIFTY	9984.80	-0.32	
BSE MIDCAP	15804.59	-0.82%	
CNX MIDCAP	7847.65	-1.39	
Nifty Top Gainer			
BHARTIARTL .	405.95	5.55	384.6
<u>HINDPETRO</u>	452.5	3.65	436.55
INFRATEL	410.7	2.71	399.85
TCS	2,500.00	1.66	2,459.25
<u>IOC</u>	417.5	1.62	410.85
Nifty Top Looser			
YESBANK	362.55	-2.78	372.9
<u>SBIN</u>	251.2	-2.24	256.95
<u>VEDL</u>	314	-2.18	321
<u>TATAMOTORS</u>	414.45	-2.16	423.6
<u>IBULHSGFIN</u>	1,257.50	-1.9	1,281.90

Securities Ban in Trade

BEML
DHFL
IBREALEST
JSWENERGY
RCOM
RELCAPITAL

Domestic-

Corporate-

- Indiabulls Ventures: IVL Finance, a subsidiary of Indiabulls Ventures, is
 getting into consumer finance with a big push on personal loans by
 tapping the existing customers of banks. It would fund those who are
 not on the list for pre-approved loans at lenders like HDFC
 Bank and State Bank of India and take the risk on its books.
- IndusInd Bank: The lender wiill report quarterly earnings today. Brokerage Motilal Oswal Securities expects non-interest income for the lender to grow 25 per cent, supported by healthy fee income growth of 22 per cent. Stronger contribution of third-party distribution fees owing to increased inflows into MFs and insurance industry should support higher third-party distribution fees.
- Larsen & Toubro: Larsen & Toubro (L&T) said it has entered into a
 definitive agreement with ESAB Holdings Ltd for selling its entire stake
 in wholly-owned arm EWAS Alloys Ltd for Rs 522 crore.
- Sun Pharma: Sun Pharmaceutical Industries today said it has received establishment inspection report (EIR) from the US health regulator for its Dadra facility.
- Banks: Lenders are planning to seek regulatory exemption from taking the second lot of defaulters to bankruptcy courts as such proceedings tend to erode value of assets, said three bankers familiar with the discussions
- Lupin: The drugmaker said it has acquired Symbiomix Therapeutics, a
 US-based company specialising in drugs for gynaecologic infections, for
 cash considerations of \$150 million. The acquisition, made through the
 firm's US subsidiary Lupin Pharmaceuticals, involves upfront payment of
 \$50 million, other time-based payments, and sales-based contingent
 payments.

Comments-

The benchmark indices pared entire gains to end lower with the Nifty slipping below its crucial 10,000 mark as focus now shifted to the September-quarter earnings season, which is expected to be subdued due to the impact of the goods and services tax.

Wallfort Research Page 1 of 2



Wallfort Research is also available on Bloomberg < Code WFSR>

Disclaimer: This document has been prepared by the Research Division of Wallfort Financial Services Ltd. Mumbai, India (WFSL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of WFSL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, WFSL has not independently verified the accuracy or completeness of the same. Neither WFSL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either WFSL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

Disclosure: Wallfort Financial Services Ltd. / its affiliates entities / employees may hold a position in the stock(s) recommended above.

Wallfort Research Page 2 of 2